R0V Stock Overview
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Revenio Group Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €31.84 |
| 52 Week High | €33.32 |
| 52 Week Low | €31.36 |
| Beta | 1.45 |
| 1 Month Change | 0% |
| 3 Month Change | -0.13% |
| 1 Year Change | n/a |
| 3 Year Change | -7.84% |
| 5 Year Change | n/a |
| Change since IPO | 106.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| R0V | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -3.5% |
| 1Y | n/a | -14.4% | 13.6% |
Return vs Industry: Insufficient data to determine how R0V performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how R0V performed against the German Market.
Price Volatility
| R0V volatility | |
|---|---|
| R0V Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: R0V has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine R0V's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 217 | Jouni Toijala | www.reveniogroup.fi |
Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging and DRSplus, a device for detection of diabetic retinopathy; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.
Revenio Group Oyj Fundamentals Summary
| R0V fundamental statistics | |
|---|---|
| Market cap | €607.38m |
| Earnings (TTM) | €19.15m |
| Revenue (TTM) | €98.03m |
31.7x
P/E Ratio6.2x
P/S RatioIs R0V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R0V income statement (TTM) | |
|---|---|
| Revenue | €98.03m |
| Cost of Revenue | €28.01m |
| Gross Profit | €70.02m |
| Other Expenses | €50.87m |
| Earnings | €19.15m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 26, 2023
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 71.43% |
| Net Profit Margin | 19.54% |
| Debt/Equity Ratio | 19.4% |
How did R0V perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield50%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/05 04:06 |
| End of Day Share Price | 2023/06/09 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revenio Group Oyj is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pia Rosqvist-Heinsalmi | Carnegie Investment Bank AB |
| Daniel Lepistö | Danske Bank |
| null null | Evli Bank plc |